semaglutide 2.4 mg obesity Efficacy and safety of once weekly 2·4 for weight management in a predominantly east Asian population with overweight or (STEP 7): a double-blind, multicentre, randomised controlled trial A new era': How semaglutide

FDA exclusivity Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not

New Delhi, April 1: Medications known as GLP-1 receptor agonists are rapidly gaining popularity in India for managing Type 2 Diabetes and obesity, prompting authorities to tighten oversight amid rising concerns over misuse and potential health risks

Additional GLP-1 and GCG agonists, including pemvidutide and efinopeglutide, are in clinical development for obesity, with particular interest in their potential benefits for metabolic dysfunction-associated liver disease (MASLD) [83]

However, the rapid weight loss and lack of adequate nutrient intake you can experience on GLP-1s can trigger temporary hair loss

Some individuals also chose to stop treatment because of rapid weight loss